Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul 9:2020:6923103.
doi: 10.1155/2020/6923103. eCollection 2020.

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib

Affiliations
Case Reports

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib

Sumaira Khalil et al. Case Rep Oncol Med. .

Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare entity of neoplastic origin. It usually occurs in children and adolescents and most commonly involves pulmonary and gastrointestinal sites. Here, the authors present two cases; one is the nine months old boy with a subcutaneous IMT in the left temporal region that was treated successfully with surgical resection. To the best of our knowledge, this is the first reported case of a subcutaneous IMT in this particular region. The second is an eight years old girl with an IMT of the right hemi-pelvis. The mass had complete surgical excision with clear margins and no residual disease. She was kept on regular follow-up with ultrasound abdomen. However, her disease relapsed with the appearance of lesions in right iliac fossa, right ovary, and liver. Biopsy of the relapsed abdominal mass confirmed ALK-positive IMT. She was treated with ALK inhibitor Crizotinib. She was monitored with regular blood complete picture, hepatic and renal function test, and ultrasound abdomen. Her lesions started regressing within one month, and she achieved complete remission after 6 months of treatment.

PubMed Disclaimer

Conflict of interest statement

We have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
CT scan brain showing soft tissue mass in right temporal area under the skin not involving bone and brain.
Figure 2
Figure 2
Microscopic appearance of inflammatory myofibroblastic tumor. Spindle cells with inflammatory cells.
Figure 3
Figure 3
Immunohistochemical staining showing ALK Positivity.

Similar articles

Cited by

References

    1. Munoz Moya J. E., Alfaro Aguirre M. O., Leiva Silva M., Kakarieka Weisskopf E., Lopez Saez M. T. Inflammatory myofibroblastic tumor: variable presentation of the same pathology. Revista Chilena de Pediatría. 2019;90(3):328–335. doi: 10.32641/rchped.v90i3.898. - DOI - PubMed
    1. Alshammari H. K., Alzamami H. F., Ashoor M., Almarzouq W. F., Kussaibi H. A rare presentation of inflammatory myofibroblastic tumor in the nasolabial fold. Case Reports in Otolaryngology. 2019;2019:5. doi: 10.1155/2019/3257697.3257697 - DOI - PMC - PubMed
    1. Tothova Z., Wagner A. J. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Current Opinion in Oncology. 2012;24(4):409–413. doi: 10.1097/CCO.0b013e328354c155. - DOI - PubMed
    1. Lovly C. M., Gupta A., Lipson D., et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discovery. 2014;4(8):889–895. doi: 10.1158/2159-8290.CD-14-0377. - DOI - PMC - PubMed
    1. Gasparotti R., Zanetti D., Bolzoni A., Gamba P., Morassi M. L., Ungari M. Inflammatory myofibroblastic tumor of the temporal bone. American Journal of Neuroradiology. 2003;24(10):2092–2096. - PMC - PubMed

Publication types

LinkOut - more resources